Literature DB >> 2159365

Differences between normal and ras-transformed NIH-3T3 cells in expression of the 170kD and 180kD forms of topoisomerase II.

R D Woessner1, T D Chung, G A Hofmann, M R Mattern, C K Mirabelli, F H Drake, R K Johnson.   

Abstract

The activity of topoisomerase II and the cellular content of the 170kD and 180kD forms of the enzyme were studied as functions of transformation and growth state by using normal and ras-transformed NIH-3T3 cells. Total topoisomerase II activity, as measured by the unknotting of P4 DNA, was higher in ras-transformed than in normal cells in similar growth states, and was higher in exponentially growing than in plateau cells for both cell lines. Total topoisomerase II levels, as measured by immunoblotting, showed a similar dependence on transformation and growth state. The relative amounts of the 170kD and 180kD forms of the enzyme varied as a function of transformation and growth state. The proportion of 170kD topoisomerase II was higher in ras-transformed than in untransformed cells and depended much less on growth state in the ras-transformed cells. The topoisomerase II activity in extracts of ras-transformed cells was more sensitive to inhibition by teniposide and merbarone, drugs which selectively inhibit the 170kD form of topoisomerase II. The ras-transformed cells were also more sensitive to the cytotoxic effects of these drugs. An increase in the relative cellular content of 170kD topoisomerase II is characteristic of ras-transformed 3T3 cells, and the levels of this form of the enzyme appear to be less dependent on proliferation state than in untransformed cells. The susceptibility of certain tumors to killing by topoisomerase II-directed drugs may be due to a higher proportion of 170kD enzyme as well as a higher level of total topoisomerase II activity.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2159365

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  21 in total

1.  Influence of cell cycle and oncogene activity upon topoisomerase IIalpha expression and drug toxicity.

Authors:  D W Stacey; M Hitomi; G Chen
Journal:  Mol Cell Biol       Date:  2000-12       Impact factor: 4.272

2.  DNA topoisomerase II alpha is the major chromosome protein recognized by the mitotic phosphoprotein antibody MPM-2.

Authors:  S Taagepera; P N Rao; F H Drake; G J Gorbsky
Journal:  Proc Natl Acad Sci U S A       Date:  1993-09-15       Impact factor: 11.205

3.  In vivo etoposide-resistant C6 glioma cell line: significance of altered DNA topoisomerase II activity in multi-drug resistance.

Authors:  T Taki; T Ohnishi; N Arita; S Hiraga; T Hayakawa
Journal:  J Neurooncol       Date:  1998-01       Impact factor: 4.130

4.  p53 regulates the minimal promoter of the human topoisomerase IIalpha gene.

Authors:  M I Sandri; R J Isaacs; W M Ongkeko; A L Harris; I D Hickson; M Broggini; F Vikhanskaya
Journal:  Nucleic Acids Res       Date:  1996-11-15       Impact factor: 16.971

5.  A topoisomerase II-like protein is part of an inducible DNA-binding protein complex that binds 5' of an immunoglobulin promoter.

Authors:  C F Webb; K L Eneff; F H Drake
Journal:  Nucleic Acids Res       Date:  1993-09-11       Impact factor: 16.971

Review 6.  Structure and function of type II DNA topoisomerases.

Authors:  P M Watt; I D Hickson
Journal:  Biochem J       Date:  1994-11-01       Impact factor: 3.857

7.  Active heterodimers are formed from human DNA topoisomerase II alpha and II beta isoforms.

Authors:  H Biersack; S Jensen; I Gromova; I S Nielsen; O Westergaard; A H Andersen
Journal:  Proc Natl Acad Sci U S A       Date:  1996-08-06       Impact factor: 11.205

8.  Phosphorylation and stabilization of topoisomerase IIα protein by p38γ mitogen-activated protein kinase sensitize breast cancer cells to its poisons.

Authors:  Xiaomei Qi; Songwang Hou; Adrienne Lepp; Rongshan Li; Zainab Basir; Zhenkun Lou; Guan Chen
Journal:  J Biol Chem       Date:  2011-08-30       Impact factor: 5.157

9.  Topoisomerase II alpha is required for embryonic development and liver regeneration in zebrafish.

Authors:  Michael Dovey; E Elizabeth Patton; Teresa Bowman; Trista North; Wolfram Goessling; Yi Zhou; Leonard I Zon
Journal:  Mol Cell Biol       Date:  2009-04-20       Impact factor: 4.272

10.  Molecular characterization of the in vivo alkylating agent resistant murine EMT-6 mammary carcinoma tumors.

Authors:  D Chatterjee; C J Liu; D Northey; B A Teicher
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.